Third dose of COVID-19 vaccine strongly shields against Delta variant, says Pfizer data

Peter Hotez, MD, PhD, of the Baylor College of Medicine, Houston, told CNN viewers, "In the UK, Scotland, and Canada there are now three studies showing >80% protection, so pretty close to what we've seen. That's the reason why we don't need to be concerned right now about getting a booster."

Reported protection against the Delta variant has been reported at 72% after one dose of the Moderna vaccine and 64% after two doses of the Pfizer/BioNTech vaccine. More data is needed on the protection afforded against the Delta variant by the Johnson & Johnson vaccine.

Since the data has not been peer-reviewed yet, Pfizer set off alarms by releasing data on a third dose prior to informing the CDC and NIH and has apologized. Pfizer and BioNtech expect to publish more definitive data about the analysis and to share all accumulated data as part of ongoing discussions with the FDA, EMA, and other regulatory authorities in the coming weeks. Application for emergency use authorization in the US is planned for August.

Regulators will determine whether, and which populations, may need a third dose of the Pfizer/BioNTech vaccine. If recommended, immunocompromised, older adults will receive it initially.

Reference:

For more information refer to:

https://s21.q4cdn.com/317678438/files/doc_financials/2021/q2/Q2-2021-Earnings-Charts-FINAL.pdf